Published: July 2020
Given the anticipated increase in demand for vaccines, stakeholders are actively focusing on the development and validation of novel delivery devices, in order to deal with legacy challenges mostly related to large scale immunization campaigns
Roots Analysis has announced the addition of “Novel Vaccine Delivery Devices Market, 2019-2030” report to its list of offerings.
Of late, there has been an evident shift in interest to non-invasive immunization methods, which include oral, intranasal and transdermal modes of administration. Currently, many biopharmaceutical companies and clinical research institutes are engaged in the development of novel vaccine delivery systems, taking into consideration the specific requirements of large-scale immunization initiatives. As a result, significant efforts have been put into the development of drug delivery technologies / devices, such as microneedle patches, electroporation-based needle free injection systems, jet injectors, inhalation-based delivery systems, biodegradable implants and certain novel types of oral delivery systems.
To order this 500+ page report, which features 90+ figures and 160+ tables, please visit this link
Over 130 novel vaccine delivery devices are presently available / under development
Close to 80% of the devices are currently in preclinical / clinical stage and the rest are marketed. It is worth highlighting that majority of the novel vaccine delivery devices are autoinjectors (42%) and microneedle patches (27%).
Close to 75 companies presently claim to develop of novel vaccine delivery devices, globally
Around 55% of the players engaged in this domain are small-sized companies. It is worth highlighting that 20 companies were founded in the last few years (2010-2017). Further, majority (55%) of the device developers are located in North America, primarily in the US.
Partnership activity within this domain has grown at a CAGR of 28%, between 2014 and 2018
Maximum number of partnerships were observed in 2018 indicating an increase in the activity in this domain. Majority of these agreements were reported to be R&D and product development agreements, representing over 50% of the total number of instances.
More than 500 marketed and clinical-stage vaccines have been identified as likely candidates to be developed in combination with novel vaccine delivery devices
The report provides insights on over 500+ marketed and clinical-stage vaccines, assessing the likelihood of whether they may be developed in combination with novel vaccine delivery devices. The analysis takes into consideration route of administration, target disease indication, type of active ingredient, dosage form and target patient population.
North America and Europe are anticipated to capture over 70% of the overall market share by 2030
The current market is driven by the sales of novel vaccine delivery devices designed for intramuscular administration (over 75%), followed by those that facilitate subcutaneous administration (16%). Further, jet injectors currently capture 85% of the overall market share (2019). However, by 2030, electroporation-based needle free injection systems are anticipated to capture the dominant share (53%) in the market.
To request a sample copy / brochure of this report, please visit this link
The USD 1.5 billion (by 2030) financial opportunity within the novel vaccine delivery devices market has been analyzed across the following segments:
The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:
The research covers profiles of key players developing novel vaccine delivery devices, featuring an overview of the company, its service portfolio, details on device functions and capabilities, and an informed future outlook.
For additional details, please visit
or email email@example.com
You may also be interested in the following titles:
+1 (415) 800 3415
+44 (122) 391 1091
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry